News

U.S. Centers for Disease Control Engages BioTrove OpenArray™ Technology to Evaluate Food Safety

U.S. Centers for Disease Control Engages BioTrove OpenArray™ Technology to Evaluate Food Safety

High-Throughput System Enables Rapid Identification of Bacteria in Food Sources, Facilitates Swift Public Health Action

Woburn, MA, September 25, 2007 – BioTrove, Inc. today announced that scientists at the U.S. Centers for Disease Control (CDC), Coordinating Center for Infectious Disease (CCID) will use the BioTrove OpenArray™ technology platform to identify bacterial strains in tainted food, beginning with E. coli and Salmonella and soon others, such as botulism. Though not an endorsement of the product, the agency’s purchase of its new OpenArray NT Cycler follows a successful collaboration around the 2006 spinach-based E. coli outbreak, in which CDC scientists employed OpenArray SNP Genotyping technology to discriminate the outbreak source and compare the results with current gel-based analyses.

“The ability to evaluate bacteria based on single nucleotide polymorphisms (SNPs) allows CDC researchers to identify quickly the type of bacteria, as well as the particular strain from among hundreds of variations – in turn enabling rapid, appropriate action to protect the public,” said Kevin Munnelly, General Manger, Genomics Business Unit, BioTrove, Inc. “OpenArray is a high-throughput, high-accuracy technology that can help CDC scientists do their job faster and better.”

For routine testing, or in the case of a bacterial outbreak in food such as beef or spinach, CDC researchers conduct analyses to first determine whether a contaminant is present (e.g., Salmonella, E. coli), and then, to identify the specific strain. If an epidemiological study is required, the ability to pinpoint bacterial strain(s) and compare to other outbreak sites enables the CDC to determine if the outbreaks are likely connected, and if so, to discover the source.

“BioTrove is committed to advancing research that improves public health, and our work with the CDC is one of the clearest examples of how BioTrove technology directly impacts society,” said Al Luderer, Ph.D., president and CEO, BioTrove. “From food- and water-supply safety to large-population studies of cardiovascular risk factors, BioTrove is proud to enable groundbreaking research across multiple fields touching public health.”

BioTrove expects to install the OpenArray NT Cycler at CDC facilities in Atlanta, Georgia, in early October. Financial terms were not disclosed.

About BioTrove, Inc.

BioTrove, Inc. offers two innovative technology platforms: RapidFire™, which enables the acceleration of drug discovery and pipeline decisions, and OpenArray™, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health. With more than half of the world’s ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove’s products and services ensure that an industry committed to accuracy and speed can meet business goals.

RapidFire™ Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.

The OpenArray™ Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray™ system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.

For more information, please visit www.biotrove.com or contact:

Dr. Albert Luderer, President and CEO
BioTrove, Inc.
781-721-3648
info@biotrove.com

Arielle Bernstein
Makovsky + Company
212-508-9643
abernstein@makovsky.com

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184